-
Mashup Score: 0Tandem CD20-CD19-Directed CAR T-Cell Therapy for Relapsed/Refractory DLBCL: Zamtocabtagene Autoleucel - 6 hour(s) ago
Nirav Shah, MD, discusses findings from an interim analysis of the phase 2 DALY II trial, which is the first pivotal trial evaluating tandem CD20-CD19 directed CAR T-cell product, zamtocabtagene autoleucel, for patients with relapsed/refractory DLBCL.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0Glofitamab Plus Gemcitabine and Oxaliplatin Demonstrates Benefit for Patients With R/R Diffuse Large B-Cell Lymphoma - 7 month(s) ago
Jeremy Abramson, MD, shares data from the 2024 EHA Congress from the STARGLO trial on the survival benefit demonstrated by glofitamab plus gemcitabine and oxaliplatin (GemOx) therapy vs rituximab plus GemOx for patients with R/R DLBCL.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Oncologists1Tweet-
Jeremy Abramson, MD, discusses the benefit of treatment with CD20-CD3 bispecific antibody glofitamab plus gemcitabine and oxaliplatin (GemOx) vs rituximab-GemOx for patients with R/R #DLBCL after 1 or more prior line of therapy. Learn more: https://t.co/jQ4zEfpUQJ #medtwitter https://t.co/8OrKOs2i7c
-
Nirav Shah, MD, discusses findings from the phase 2 DALY II trial, for patients with relapsed/refractory #DLBCL. Learn more: https://t.co/PPiRO53CRF #MedTwitter https://t.co/n1qZDCXHTy